We use cookies to deliver the best possible experience on our website. To learn more, visit our Privacy Policy. By continuing to use this site, or closing this box, you consent to our use of cookies.

X

Sources

1McDougall, C., McKay, G. A., & Fisher, M. Drugs for Diabetes: Part 6 GLP-1 Receptor Agonists. Br. J Cardiol. 2011;18(4):167-169.

2McDougall, C., McKay, G. A., & Fisher, M. Drugs for Diabetes: Part 6 GLP-1 Receptor Agonists. Br. J Cardiol. 2011;18(4):167-169.

3Garber, A. J. Long Acting Glucagon-Like Peptide 1 Receptor Agonists. Diabetes Care 2011 May; 34(Supplement 2): S279-S284. https://doi.org/10.2337/dc11-s231

4Prasad-Reddy, L., and Isaacs, D. A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs Context. 2015; 4: 212283. Published online 2015 Jul 9. doi:  10.7573/dic.212283

5Cowan & Company. Therapeutic Categories Outlook: Diabetes/Obesity. Equity Research September 2016, p. 514-15.

6McKee, S. (2016, December 6). Novo files once-weekly GLP-1 analogue semaglutide. Retrieved from http://www.pharmatimes.com/news/novo_files_once-weekly_glp-1_analogue_semaglutide_1180190

 

Previous Next
Aileen Kinsella

Aileen Kinsella

Director, Segment Marketing, Pharma

Subscribe to receive the latest blog post